Blog

Important drug development questions that model-based meta-analysis answers

Explore drug development questions that model-based meta-analysis answers, from competitive positioning to dose selection &…

Danielle Pillsbury2026 年 7 月 23 日

Blog

Why the most important Phase 3 decisions should be made before Phase 3

Learn how advanced modeling for reimbursement strategy using MBMA and QSP strengthens payer evidence and…

Certara2026 年 3 月 24 日

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026 年 3 月 4 日

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

Certara2026 年 1 月 22 日

Publication

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

This study synthesizes data from a large body of clinical trials to evaluate rates of…

Certara2025 年 12 月 18 日

Publication

Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…

Certara2025 年 11 月 5 日

Publication

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

Bridge across studies with Model-based Meta Analysis, incorporating broader data & synthetic patients to enhance…

Certara2025 年 10 月 31 日

Guide

MBMA vs. Meta-Analysis: Quick Comparison Guide

Discover how Model-Based Meta-Analysis (MBMA) outperforms traditional meta-analysis in drug development by predicting outcomes, informing…

Certara2025 年 10 月 8 日

Blog

基于模型的荟萃分析（MBMA）在 GSK 的应用：对战略和临床试验的实际影响

GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…

Certara2025 年 7 月 31 日

Blog

5 大临床开发挑战 — 基于模型的荟萃分析（MBMA）助力应对

2025 年 6 月 30 日 Drug development is increasingly defined by its complexity. Teams must navigate rising…

Certara2025 年 6 月 30 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation – MBMA

Important drug development questions that model-based meta-analysis answers

Why the most important Phase 3 decisions should be made before Phase 3

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

MBMA vs. Meta-Analysis: Quick Comparison Guide

基于模型的荟萃分析（MBMA）在 GSK 的应用：对战略和临床试验的实际影响

5 大临床开发挑战 — 基于模型的荟萃分析（MBMA）助力应对

订阅时事通讯

快捷链接

解决方案

联系我们